Baldwin Wealth Partners’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-304
| Closed | -$25.5K | – | 549 |
|
|
2024
Q3 | $25.5K | Buy |
304
+33
| +12% | +$2.52K | ﹤0.01% | 661 |
|
|
2024
Q2 | $18.6K | Sell |
271
-6,504
| -96% | -$434K | ﹤0.01% | 469 |
|
|
2024
Q1 | $496K | Sell |
6,775
-8,868
| -57% | -$682K | 0.04% | 148 |
|
|
2023
Q4 | $1.27M | Sell |
15,643
-16,507
| -51% | -$1.28M | 0.1% | 96 |
|
|
2023
Q3 | $2.41M | Sell |
32,150
-895
| -3% | -$68.8K | 0.21% | 80 |
|
|
2023
Q2 | $2.55M | Sell |
33,045
-2,042
| -6% | -$163K | 0.21% | 85 |
|
|
2023
Q1 | $2.91M | Sell |
35,087
-318
| -0.9% | -$26.3K | 0.25% | 80 |
|
|
2022
Q4 | $3.04M | Buy |
35,405
+35,162
| +14,470% | +$2.78M | 0.28% | 79 |
|
|
2022
Q3 | $15K | Hold |
243
| – | – | ﹤0.01% | 473 |
|
|
2022
Q2 | $15K | Sell |
243
-15
| -6% | -$929 | ﹤0.01% | 498 |
|
|
2022
Q1 | $15K | Buy |
258
+7
| +3% | +$447 | ﹤0.01% | 503 |
|
|
2021
Q4 | $18K | Hold |
251
| – | – | ﹤0.01% | 458 |
|
|
2021
Q3 | $18K | Hold |
251
| – | – | ﹤0.01% | 465 |
|
|
2021
Q2 | $17K | Hold |
251
| – | – | ﹤0.01% | 481 |
|
|
2021
Q1 | $16K | Sell |
251
-100
| -28% | -$6.45K | ﹤0.01% | 477 |
|
|
2020
Q4 | $20K | Hold |
351
| – | – | ﹤0.01% | 403 |
|
|
2020
Q3 | $22K | Hold |
351
| – | – | ﹤0.01% | 377 |
|
|
2020
Q2 | $27K | Hold |
351
| – | – | ﹤0.01% | 357 |
|
|
2020
Q1 | $26K | Buy |
351
+136
| +63% | +$9.4K | ﹤0.01% | 349 |
|
|
2019
Q4 | $14K | Sell |
215
-143
| -40% | -$9.31K | ﹤0.01% | 433 |
|
|
2019
Q3 | $23K | Sell |
358
-70
| -16% | -$4.58K | ﹤0.01% | 392 |
|
|
2019
Q2 | $29K | Sell |
428
-20
| -4% | -$1.32K | ﹤0.01% | 361 |
|
|
2019
Q1 | $29K | Sell |
448
-360
| -45% | -$23.9K | ﹤0.01% | 361 |
|
|
2018
Q4 | $51K | Buy |
808
+259
| +47% | +$18.1K | 0.01% | 280 |
|
|
2018
Q3 | $42K | Sell |
549
-70
| -11% | -$5.29K | 0.01% | 333 |
|
|
2018
Q2 | $44K | Buy |
619
+100
| +19% | +$7.06K | 0.01% | 329 |
|
|
2018
Q1 | $39K | Buy |
519
+121
| +30% | +$9.62K | 0.01% | 324 |
|
|
2017
Q4 | $29K | Buy |
398
+118
| +42% | +$8.96K | ﹤0.01% | 344 |
|
|
2017
Q3 | $23K | Hold |
280
| – | – | ﹤0.01% | 350 |
|
|
2017
Q2 | $20K | Hold |
280
| – | – | ﹤0.01% | 375 |
|
|
2017
Q1 | $19K | Hold |
280
| – | – | ﹤0.01% | 372 |
|
|
2016
Q4 | $20K | Hold |
280
| – | – | ﹤0.01% | 369 |
|
|
2016
Q3 | $22K | Sell |
280
-3,220
| -92% | -$262K | ﹤0.01% | 368 |
|
|
2016
Q2 | $292K | Sell |
3,500
-178
| -5% | -$15.8K | 0.06% | 143 |
|
|
2016
Q1 | $338K | Sell |
3,678
-1,683
| -31% | -$152K | 0.06% | 167 |
|
|
2015
Q4 | $542K | Sell |
5,361
-519
| -9% | -$54K | 0.09% | 153 |
|
|
2015
Q3 | $577K | Buy |
5,880
+50
| +0.9% | +$5.55K | 0.1% | 158 |
|
|
2015
Q2 | $683K | Hold |
5,830
| – | – | 0.1% | 154 |
|
|
2015
Q1 | $572K | Hold |
5,830
| – | – | 0.08% | 161 |
|
|
2014
Q4 | $550K | Buy |
5,830
+140
| +2% | +$14.5K | 0.08% | 170 |
|
|
2014
Q3 | $612K | Hold |
5,690
| – | – | 0.09% | 168 |
|
|
2014
Q2 | $472K | Buy |
5,690
+625
| +12% | +$48.6K | 0.07% | 173 |
|
|
2014
Q1 | $359K | Hold |
5,065
| – | – | 0.06% | 189 |
|
|
2013
Q4 | $380K | Hold |
5,065
| – | – | 0.06% | 179 |
|
|
2013
Q3 | $318K | Buy |
+5,065
| New | +$303K | 0.06% | 185 |
|
Other funds holding GILD
Baldwin Wealth Partners's GILD Position: Q4 2024 in Review
Baldwin Wealth Partners sold out of Gilead Sciences (GILD) in Q4 2024, closing a stake of 304 shares — an estimated $25.5K sold.
Baldwin Wealth Partners first reported a position in GILD in Q3 2013 and held it in 45 quarters. The position peaked at $3.04M in Q4 2022. 1,887 funds tracked by Wall St. Rank hold GILD as of Q4 2024.
- Baldwin Wealth Partners reported no remaining Gilead Sciences position as of Q4 2024 after selling out during the quarter.
- Baldwin Wealth Partners sold 304 Gilead Sciences shares in Q4 2024, an estimated $25.5K.
- Baldwin Wealth Partners first reported a position in Gilead Sciences in Q3 2013 and held it in 45 quarters.
- Baldwin Wealth Partners's Gilead Sciences position peaked at $3.04M in Q4 2022.
- 1,887 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2024.
Based on Baldwin Wealth Partners's 13F filing for Q4 2024, filed 22 Jan 2025.